Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy XR (topiramate) extended-release capsules

Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy® XR (topiramate) extended-release capsules Ahmedabad, January 13, 2017 Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that they have finalized an agreement with Upsher-Smith Laboratories, Inc. to settle all outstanding patent litigation related to Qudexy ® XR (topiramate) extended -release capsules. Under the terms of the agreement, Upsher -Smith grants Zydus a license to market Zydus’ generic version of Qudexy ® XR beginning on March 1 9, 2020, or earlier under certain circumstances. Other terms of the settlement were not disclosed. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcar e therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

The release as fetched from its publisher. zyduslife.com ↗